Brief: Veradermics’ Oral Vdphl01 Achieved Early, Consistent, And Robust Hair Growth In Positive Phase 3 ‘304’ Clinical Trial In Male Pattern Hair Loss
BRIEF-Veradermics’ Oral Vdphl01 Achieved Early, Consistent, And Robust Hair Growth In Positive Phase 3 ‘304’ Clinical Trial In Male Pattern Hair Loss Oct 19 (Reuters) - Veradermics, Incorporated MANE.N:
VERADERMICS’ ORAL VDPHL01 ACHIEVED EARLY, CONSISTENT, AND ROBUST HAIR GROWTH IN POSITIVE PHASE 3 ‘304’ CLINICAL TRIAL IN MALE PATTERN HAIR LOSS
VERADERMICS, INCORPORATED - VDPHL01 MEETS ALL PRIMARY AND SECONDARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE IN PHASE 3
VERADERMICS, INCORPORATED - COMPLETES ENROLLMENT FOR FEMALE PATTERN HAIR LOSS TRIAL; TOPLINE DATA EXPECTED H1 2027
VERADERMICS, INCORPORATED - 78.8% (QD) AND 85.0% (BID) OF PARTICIPANTS REPORTED VISIBLE IMPROVEMENT IN PRO AT MONTH 6
VERADERMICS, INCORPORATED - VDPHL01 DEMONSTRATES FAVORABLE SAFETY PROFILE IN OVER 1,000 PARTICIPANTS WITH NO NEW SAFETY SIGNALS
Source text: ID:nBw8bGPfba
Further company coverage: MANE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veradermics, Incorporated
See all newsVeradermics' oral hair-loss drug shown to boost hair growth in late-stage study (updated)
Brief: Veradermics’ Oral Vdphl01 Achieved Early, Consistent, And Robust Hair Growth In Positive Phase 3 ‘304’ Clinical Trial In Male Pattern Hair Loss
Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
Veradermics Q2 net loss widens on higher expenses